Double-class-exposed* patients are a difficult-to-treat population with limited treatment options1-3

CLL cell icon

CLL and SLL may start off indolent, but as the disease progresses, it can become more aggressive and difficult to treat4-6

Doctor wearing stethoscope icon

There is no standard of care, and treatment options are limited for patients who have received a BTKi and a BCL-2i.7,8

Cumulative toxicities cycle icon

Cumulative toxicities can also arise from disease progression and long-term therapies9-14

Patients with R/R CLL or SLL need more treatment options that deliver deep and durable responses1,2

Current treatment options are associated with poor outcomes for double-class-exposed* patients after the immediate next line of therapy15†

Figures are based on real-world data of 548 patients with CLL or SLL exposed to both a BTKi and BCL-2i12†

Extremely rare CR15

34% ORR12†

13-month mDOR12†
(95% CI: 10.6, 19.5)

Achieving uMRD is uncommon16

Patients with R/R CLL or SLL need more treatment options that deliver deep and durable responses1,2

*Double-class-exposed patients have received both a BTKi and BCL-2i.2

Data from a retrospective observational study of 548 patients with CLL and exposure to both a BTKi and BCL-2i. The data utilized were from the Flatiron Health electronic health record-derived database, and originated from ~280 cancer clinics in the U.S. Patients had at least 2 clinic visits in the database showing evidence of receiving systemic therapy on or after January 1, 2011. Comparisons between real-world and clinical-trial data of patients with CLL should be made with caution.12

BCL-2i, B-cell lymphoma-2 inhibitor; BTKi, Bruton tyrosine kinase inhibitor; CI, confidence interval; CLL, chronic lymphocytic leukemia; CR, complete response; mDOR, median duration of response; ORR, overall response rate; R/R, relapsed or refractory; SLL, small lymphocytic lymphoma; uMRD, undetectable minimal residual disease.

This website is best viewed
using the horizontal display on
your tablet device.

This website is best viewed
using the vertical display on
your mobile device.

  1. Patel K, Pagel JM. Current and future treatment strategies in chronic lymphocytic leukemia. J Hematol Oncol. 2021;14(1):69. doi:10.1186/s13045-021-01054-w
  2. Siddiqi T, Maloney DG, Kenderian SS, et al. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study. Lancet. 2023;402(10402):641-654. doi:10.1016/S0140-6736(23)01052-8
  3. O’Brien SM, Furman RR, Byrd JC, Smith A. Clinical roundtable monograph: unmet needs in the treatment of chronic lymphocytic leukemia: integrating a targeted approach. Clin Adv Hematol Oncol. 2014;12(1 suppl 3):1-13.
  4. Strati P, Keating MJ, O’Brien SM, et al. Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion. Haematologica. 2014;99(8):1350-1355. doi:10.3324/haematol.2014.104661
  5. Gaidano G, Rossi D. The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment. Hematology Am Soc Hematol Educ Program. 2017;2017(1):329-337. doi:10.1182/asheducation-2017.1.329
  6. Skånland SS, Mato AR. Overcoming resistance to targeted therapies in chronic lymphocytic leukemia. Blood Adv. 2021;5(1):334-343. doi:10.1182/bloodadvances.2020003423
  7. Roeker LE, Mato AR. Approaches for relapsed CLL after chemotherapy-free frontline regimens. Hematology Am Soc Hematol Educ Program. 2020;2020(1):10-17. doi:10.1182/hematology.2020000168
  8. Lew TE, Lin VS, Cliff ER, et al. Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition. Blood Adv. 2021;5(20):4054-4058. doi:10.1182/bloodadvances.2021005083
  9. Burger JA, O’Brien S. Evolution of CLL treatment — from chemoimmunotherapy to targeted and individualized therapy. Nat Rev Clin Oncol. 2018;15(8):510-527. doi:10.1038/s41571-018-0037-8
  10. Simon F, Bohn JP. Next-generation sequencing-optimal sequencing of therapies in relapsed/refractory chronic Lymphocytic leukemia (CLL). Curr Oncol Rep. 2023;25(10):1181-1189. doi:10.1007/s11912-023-01454-w
  11. Bennett R, Anderson MA, Seymour JF. Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia. J Hematol Oncol. 2023;16(1):72. doi:10.1186/s13045-023-01469-7
  12. Eyre TA, Hess LM, Sugihara T, et al. Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States: a real-world database study. Leuk Lymphoma. 2023;64(5):1005-1016. doi:10.1080/10428194.2023.2190436
  13. Hertler A, Flood WA, Page R, Brooks B, D’Amato SL, Kolodziej M. The challenge of developing pathways in a rapidly evolving clinical space: Chronic Lymphocytic leukemia as a case study. J Clin Pathways. 2020;6(2). doi:10.25270/jcp.2020.3.00002
  14. Lew TE, Anderson MA, Seymour JF. Promises and pitfalls of targeted agents in chronic lymphocytic leukemia. Canc Drug Resist. 2020;3(3):415-444. doi:10.20517/cdr.2019.108
  15. Mato AR, Roeker LE, Jacobs R, et al. Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy. Clin Cancer Res. 2020;26(14):3589-3596. doi:10..1158/1078-0432.CRR-19-3815
  16. Ahn IE, Farooqui MZH, Tian X, et al. Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study. Blood. 2018;131(21):2357-2366. doi:10.1182/blood-2017-12-820910